Efficacy of ligand-based targeting for the EGF system in cancer

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4879-4885

  Yotsumoto, Fusanori ^a   Sanui, Ayako ^a   Fukami, Tatsuya ^a   Shirota, Kyoko ^a   Horiuchi, Shinji ^a   Tsujioka, Hiroshi ^a   Yoshizato, Toshiyuki ^a   Kuroki, Masahide ^a   Miyamoto, Shingo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Amphiregulin; Cancer; HB EGF; Review; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PACLITAXEL; RB 200; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DIMERIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 75149129578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Citri A and Yarden Y: EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
2. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
3. Sharma SV, Bell DW, Settleman J and Harver DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
4. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW and Yokoyama S: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-552, 2003.
5. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M and Yarden: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared co-receptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995-5000, 1999.
6. Guy PM, Platko JV, Cantley LC, Cerione RA and Carraway KL 3rd: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91: 8132-8136, 1994.
7. Imai K and Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727, 2006.
8. Morgillo F and Lee HY: Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Update 8: 298-310, 2005.
9. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ and Coffey RJ: A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 272: 18926-18931, 1997.
10. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
11. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006.
12. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Research Commun 365: 555-561, 2008.
13. Martinez-Lacaci I, De Santis M, Kannan S, Bianco C, Kim N, Wallace-Jones B, Wechselberger C, Ebert AD and Salomon DS: Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells. J Cell Physiol 186: 233-242, 2001.
14. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Santamaria M, Lee DC, Prieto J and Avila MA: Novel role for amphiregulin in protection from liver injury. J Biol Chem 280: 19012-19020, 2005.
15. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J and Avila MA: Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 128: 424-432, 2005.
16. Castillo J, Erroba E, Peragorría MJ, Santamaría M, Lee DC, Prieto J, Avila MA and Berasain C: Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66: 6129-6138, 2006.
17. Beales IL: Gastrin and interleukin-1 beta stimulate growth factor secretion from cultured rabbit gastric parietal cells. Life Sci 75: 2983-2995, 2004.
18. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
19. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S and Baselga J: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283, 2003.
20. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003.
21. Massague J and Pandiella A: Membrane-anchored growth factors. Annu Rev Biochem 62: 515-541, 1993.
22. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48, 1998.
23. Koizumi F, Shimoyama T, Taguchi F, Saijo N and Nishio K: Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116: 36-44, 2005.
24. Adams TE, McKern NM and Ward CW: Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 22: 89-95, 2004.
25. Arpino G, Wiechmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
26. Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin™). J Natl Cancer Inst 93: 1852-1857, 2001.
27. Hallak H, Seiler AE, Green JS, Ross BN and Rubin R: Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J Biol Chem 275: 2255-2258, 2000.
28. El-Shewy HM, Kelly FL, Barki-Harrington L and Luttrell LM: Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I. Mol Endocrinol 18: 2727-2739, 2004.
29. Song RX, Zhang Z, Chen Y, Bao Y and Santen RJ: Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148: 4091-4101, 2007.
30. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa™') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001.
31. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB and Arteaga CL: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822, 2003.
32. She QB, Solit D, Basso A and Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9: 4340-4346, 2003.
33. Ferrer-Soler L, Vazquez-Martin A, Branet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
34. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393, 2008.
35. Nanba D, Mammoto A, Hashimoto K and Higashiyama S: Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502, 2003.
36. Kinugasa Y, Hieda M, Hori M and Higashiyama S: The carboxyl-terminal fragment of pro-HB-EGF reverses Bc16-mediated gene repression. J Biol Chem 282: 14797-14806, 2007.
37. Lin J, Hutchinson L, Gaston SM, Raab G and Freeman MR: BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276: 30127-30132, 2001.
38. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, Tanida S and Joh T: Suppression of proHB-EGF carboxyterminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res 14: 3956-3965, 2008.
39. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H and Mekada E: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004.
40. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E and Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 92: 1737-1745, 2005.
41. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E and Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease-17 expression in human ovarian cancer. Clin Cancer Res 11: 4783-4792, 2005.
42. Yagi H, Yotsumoto F and Miyamoto S: Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial mesenchymal transition. Mol Cancer Ther 7: 3441-3451, 2008.
43. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E and Miyamoto S: Synergistic antitumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 124: 1429-1439, 2009.
44. Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J and Shepard HM: Human epidermal growth factor receptor (HER-1 :HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther 7: 3223-3236, 2008.
45. Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B and Shepard HM: Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med 15: 11-20, 2009.